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Rubella is of global public health concern; >100,000 
cases of congenital rubella syndrome (CRS) are reported 
annually worldwide (1). An immunization program re-
sulted in rubella elimination in the United States during 
2004 (2). Currently, the Centers for Disease Control and 
Prevention (CDC) estimates that <10 persons are reported 
to have rubella annually in the United States (2). During 
the 8 years after rubella was eliminated (2004–2012), 79 
of rubella cases were reported, including in case-patients 
with no travel history (3). For the same period, 6 CRS 
cases were reported to CDC, 5 of which were likely im-
ported (3). The sixth case was the infant of a US-born vac-
cinated mother without known risk factors (4). During the 
next 4 years (2013–2016), 5 confirmed CRS cases were 
reported to CDC, indicating a relative increase in the total 
number of new cases in the United States. The 5 cases 
were reported by three states, Illinois (2 cases), New York 
(2 cases), and Maryland (1 case); infections were likely 
acquired in Algeria, Pakistan, Yemen, and Nigeria (US 
Centers for Disease Control and Prevention, pers. comm, 
March 2017) (5).
During early pregnancy, the mother of the case-patient 
likely acquired acute rubella infection in Saudi Arabia, 
which increased its rubella vaccine program in July 2017 to 
meet control needs (6). Maternal immunization records and 
rubella titers were not available. The infant had positive ru-
bella IgM, cataract, congenital heart disease, microcephaly, 
unilateral hearing loss, and radiolucent bone disease, meet-
ing criteria for CRS. Screening for rubella titers in early 
pregnancy is standard in the United States. The presence 
of positive maternal rubella serology at delivery does not 
always reflect maternal immunization but can be the result 
of a rubella infection in early pregnancy. A similar scenario 
was misleading in a case that was recently reported and 
resulted in late diagnosis of CRS and subsequent multiple 
exposures (6). 
Rubella-like illness in early pregnancy warrants 
testing for acute rubella infection, which offers parents 
an opportunity to decide about pregnancy outcome. For 
confirmed cases, maternal counseling and pregnancy ter-
mination may be considered. Testing for CRS is critical 
for early disease confirmation, implementation of ap-
propriate infection control, timely reporting, and possi-
ble epidemiologic investigation. Infants with CRS shed 
large quantities of virus from bodily secretions for up to 1 
year and can transmit rubella virus to susceptible persons 
(7). The presence of unimmunized persons in the United 
States (for age, personal, or medical reasons) and entry of 
persons from rubella-endemic countries enable potential 
circulation of the virus. Despite rubella elimination in the 
United States, the presence of birth defects compatible 
with CRS warrants consideration of rubella in addition to 
other congenital infections.
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A patient transferred from South Africa to Israel acquired 
a Candida auris infection. Phylogenetic analysis showed 
resemblance of C. auris to isolates from South Africa 
but not Israel, suggesting travel-associated infection. C. 
auris infection occurred weeks later in another patient 
at the same hospital, suggesting prolonged environmen-
tal persistence.
Candida auris is a multidrug-resistant yeast that has emerged over the past 3 years to cause nosocomial 
outbreaks in multiple countries. C. auris can cause serious 
invasive infections, may spread between patients, and can 
survive for months on hospital room surfaces (1). Whole-
genome sequencing has determined the presence of coun-
try-specific clades, which differ from one another by thou-
sands of single-nucleotide polymorphisms (2). The mode 
of spread between countries remains unclear. We present 
a case of international C. auris transmission related to a 
medically repatriated patient.
A previously healthy 25-year-old Israeli man (patient 
A) was admitted to a hospital in Johannesburg, South Af-
rica, after a motor vehicle accident on July 24, 2016. He 
had severe limb injury and underwent open reduction and 
internal fixation on both femurs, complicated by fat emboli, 
acute respiratory distress syndrome requiring mechanical 
ventilation, and ventilator-associated pneumonia. He was 
empirically treated with broad-spectrum antimicrobial 
drugs and caspofungin. Three weeks after the accident, he 
was transferred to the intensive care unit (ICU) of Sheba 
Medical Center, Tel Hashomer, Israel. Ten days after his 
arrival, a deep surgical-site infection developed in his left 
thigh. We initiated debridement and broad-spectrum an-
timicrobial drugs. After cultures obtained during surgery 
grew extended-spectrum β-lactamase–producing Klebsi-
ella pneumoniae and meropenem-resistant Pseudomonas 
aeruginosa, we initiated contact isolation. Two of 3 deep-
wound cultures grew C. auris. Two days later, 1 blood 
culture grew C. parapsilosis. We administered amphoteri-
cin B and appropriate antibacterial drugs, discontinuing 
amphotericin B after 10 days due to increased creatinine. 
The surgical site healed, and the patient was transferred to 
a rehabilitation unit. Rectal and skin surveillance cultures 
obtained 4 weeks after the first isolation of Candida were 
negative for C. auris. Routine ICU environmental disinfec-
tion included daily bleach cleaning of surfaces and qua-
ternary ammonium wipes of sensitive medical equipment.
In January 2017, we isolated C. auris from a urine cul-
ture obtained through a catheter of a 70-year-old patient 
(patient B) who was admitted to the Sheba Medical Center 
ICU 6 weeks after the discharge of patient A. Patient B had 
not traveled abroad recently. Surveillance cultures (urine, 
axilla, perineum) of patients in the ICU at the time of C. 
auris isolation of either patient A or B were negative for 
C. auris. One environmental sample from the floor next to 
patient B’s bed in proximity to the urinary catheter bag was 
positive for C. auris. All other environmental samples were 
negative. We removed the urinary catheter without further 
antimicrobial therapy. Strict environmental cleaning was 
performed in the ICU.
We performed drug susceptibility testing using broth 
microdilution in accordance with Clinical Laboratory 
Standards Institute methods (https://clsi.org/standards/
products/microbiology/documents/m27/) and reported re-
sults with preliminary breakpoints as published by the US 
Centers for Disease Control and Prevention (3). The study 
was approved by the Sheba Medical Center institutional 
review board.
We identified isolates as C. auris by matrix-assisted la-
ser desorption/ionization time-of-flight mass spectrometry 
(Bruker Daltonik, Bremen, Germany) and as C. parapsi-
losis by the Phoenix system (Becton Dickinson, Franklin 
Lakes, NJ, USA). Sequence alignment with C. auris type 
strain CBS10913T produced similarity scores of 98% for 
internal transcribed spacer and 100% for large subunit ribo-
somal DNA segments for all 4 strains. Internal transcribed 
spacer and large subunit sequences of isolates from both 
patients were 100% identical to strains for MRL293 and 
MRL208 from South Africa (4) and distinct from sequenc-
es of strains previously isolated in our hospital and in Tel 
Aviv (Figure) (5).
C. auris isolates from patients A and B were resistant 
to fluconazole and susceptible to anidulafungin and had 
high MICs to voriconazole (>8 μg/mL). One isolate was 
resistant to amphotericin B (MIC 2 μg/mL) (3), although a 
recent study suggested a higher epidemiologic cutoff that 
defines the isolate as susceptible (6).
Nosocomial outbreaks associated with C. auris were 
reported from several countries and continents including 
India, South Africa, Venezuela, Pakistan, and the United 
States (2,7,8). Sporadic cases were reported from Israel 
(5). Echinocandin exposure, which preceded C. auris in-
fection in patient A, was also reported in South Africa (2). 
Environmental contamination appears to be a common 
mode of C. auris spread within medical facilities (1); it 
is the suspected cause for the 2 cases reported here, de-
spite the time between them. The use of quaternary am-
monium compounds, which are less effective than bleach, 
for disinfecting equipment might contribute to persistence 
of Candida (9). 
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International travel is an increasingly recognized risk 
factor for infection with drug-resistant pathogens. Our in-
vestigation underscores the potential role of international 
travel and especially the transportation of patients between 
countries as a mode of C. auris dissemination. The wide 
genetic gap between country-specific clades allows the use 
of ribosomal DNA typing as a tool for identifying the geo-
graphic origin of specific isolates (2,5). A similar approach 
was used to demonstrate multiple transmission events into 
the United Kingdom (10).
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Cephalosporin-resistant Neisseria gonorrhoeae is a major 
public health concern. N. gonorrhoeae of multiantigen se-
quence type G1407 and multilocus sequence type 1901 is 
an internationally spreading cephalosporin-resistant clone. 
We detected 4 cases of infection with this clone in China 
and analyzed resistance determinants by using N. gonor-
rhoeae sequence typing for antimicrobial resistance.
Gonorrhea, the second most prevalent sexually trans-mitted infection (STI) globally, remains a major 
public health concern in China. From 2015 to 2016, the 
reported cases of gonorrhea in China increased by 14.7% 
(100,245 to 115,024) (1). The extended-spectrum cepha-
losporin ceftriaxone has been recommended as mono-
therapy to treat gonorrhea in China since 2007 (2), but 
resistance to this drug emerged almost at the same time 
(3). Presently, the transmission of internationally spread 
cephalosporin-resistant clones in China has become a 
threat to effectively controlling gonorrhea (4). Strains 
with N. gonorrhoeae multiantigen sequence type (NG-
MAST) G1407 and multilocus sequence type (MLST) 
1901 have been successful clones associated with cepha-
losporin resistance and have caused clinical treatment 
failures in France and Spain (5,6); these strains have also 
became the predominant clones in the United Kingdom 
(7) and Japan (8) and among US men who have sex with 
men (9). Here we report 4 cephalosporin-resistant NG-
MAST G1407/MLST 1901 clones identified out of 2,038 
isolates collected through China’s Gonococcal Resistance 
Surveillance Program during 2015–2016.
Demographic and clinical information for the 4 case-
patients are summarized in online Technical Appendix 
Table 1 (https://wwwnc.cdc.gov/EID/article/24/4/17-1817-
Techapp1.xlsx). All case-patients were adult men; gonococ-
cal isolates were obtained from urethral swab samples. The 
4 men had obvious urethral discharge and were diagnosed 
with acute urethritis. Gram staining and culture of the ure-
thral swabs were positive for gonococcal infection. One of 
the 4 patients self-reported being a man who has sex with 
men. One of the infections, occurring in Zhejiang Province, 
was treated with a single-dose regimen of spectinomycin (4 
g); the other 3 infections, occurring in the municipality of 
Chongqing, were treated with a 2-dose regimen of ceftriax-
one (1 g) administered over 2 days. Test-of-cure follow-ups 
were not performed.
All strains were transferred to the reference laboratory 
at the National Center for Sexually Transmitted Disease 
Control, Chinese Center for Disease Control and Preven-
tion. Gram staining, a rapid oxidase reaction test, and a 
carbohydrate utilization test confirmed the identification 
of N. gonorrhoeae. We determined antimicrobial suscepti-
bility to ceftriaxone (CRO), cefixime (CFM), spectinomy-
cin (SPT), azithromycin (AZM), ciprofloxacin (CIP), and 
